Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

These data suggest that EGFR inhibition using Food and Drug Administration-approved inhibitors provides a promising therapeutic approach for reduction of fibrogenesis and prevention of HCC in high-risk cirrhosis patients who can be identified and monitored by gene expression signatures.